secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2022-06-22T23:59:59+00:00
Accession:  0001104659-22-073264
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia appoints Dr. Rajeev Saggar as CMO, succeeding Dr. Tushar Shah
----------------------------------------------------------------------

- Dr. Tushar Shah terminated as CMO effective June 15, 2022; severance agreement being finalized.
- Dr. Rajeev Saggar appointed CMO effective July 18, 2022; previously VP Clinical Development at Theravance Biopharma.
- Dr. Saggar receives $475k base salary, 40% target bonus, $50k sign-on bonus, and equity grants (200k option + RSUs worth $350k).
- Dr. Saggar has over 20 years pulmonology experience and served as PI in pivotal INSPIRE study of YUTREPIA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465922073264/0001104659-22-073264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465922073264/tm2219020d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-073264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer